Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer - Vergote, I; González-Martín, A; Fujiwara, K; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators (N Engl J Med, 2024)